LCP
OREX

Lamond Capital Partners’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Lamond Capital Partners’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-189,100
Closed -$11.5M – 22
2014
Q4 		$11.5M Buy
+189,100
New +$9.5M 7.5% 6

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Lamond Capital Partners's OREX Position: Q1 2015 in Review

Lamond Capital Partners sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2015, closing a stake of 189,100 shares — an estimated $11.5M sold.

Lamond Capital Partners first reported a position in OREX in Q4 2014 and held it in 1 quarter. The position peaked at $11.5M in Q4 2014. 160 funds tracked by Wall St. Rank hold OREX as of Q1 2015.

  • Lamond Capital Partners reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Lamond Capital Partners sold 189,100 Orexigen Therapeutics, Inc. shares in Q1 2015, an estimated $11.5M.
  • Lamond Capital Partners first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and held it in 1 quarter.
  • Lamond Capital Partners's Orexigen Therapeutics, Inc. position peaked at $11.5M in Q4 2014.
  • 160 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2015.

Based on Lamond Capital Partners's 13F filing for Q1 2015, filed 12 May 2015.